Table of Contents
- Trial overview
- Who can join
- What is being measured
- Trial design and treatment groups
- Trial status and size
Trial overview
The available study of IDOR-1117-2520C is a Phase 2 interventional trial in adults with moderate to severe chronic plaque psoriasis, with or without psoriatic arthritis.[1]
The trial is authorised and is designed to explore both efficacy and safety, meaning the researchers want to see whether the study treatment may help and whether it can be used safely in this patient group.[1]
Who can join
The study is for adults with moderate to severe chronic plaque psoriasis.[1]
People may join whether or not they also have psoriatic arthritis, which is a form of joint inflammation linked to psoriasis.[1]
What is being measured
The main endpoint, or main result the study wants to measure, is the change from baseline to Week 12 in the Psoriasis Area and Severity Index (PASI) score.[1]
A PASI score is a way to measure how serious psoriasis is by looking at the affected skin and how severe the patches are.[1]
Trial design and treatment groups
This is an interventional study, which means researchers assign participants to a study treatment group.[1]
The trial compares IDOR-1117-2520C with matching placebo, which is a look-alike treatment that does not contain the study drug and helps show whether any change is due to the study treatment.[1]
The intervention listed for IDOR-1117-2520C is oral, meaning it is taken by mouth in the study setting.[1]
Trial status and size
The trial status is authorised.[1]
The planned enrollment is 30 participants, so this is a small trial meant to explore the treatment in a limited group of patients.[1]
